Silexion Therapeutics Ltd... (SLXN)
NASDAQ: SLXN
· Real-Time Price · USD
7.39
0.03 (0.41%)
At close: Aug 15, 2025, 3:56 PM
7.24
-2.03%
After-hours: Aug 15, 2025, 07:47 PM EDT
Silexion Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -12.97M | -12.57M | -12.4M | -5.09M | -3.86M | -2.62M | -1.38M | -881.39K | -882.91K | -1.23M | -1.18M | -940.63K | -978.69K | -721.11K | -483.71K | -483.71K | -288.65K |
Interest Income | 6K | 25K | 58K | 285.05K | 597.05K | 1.32M | 2.28M | 2.58M | 2.42M | 1.69M | 694.93K | 176.68K | 15.08K | 6.37K | 4.19K | 2.42K | 676.00 |
Pretax Income | -16.83M | -16.51M | -16.44M | -5.38M | -3.73M | -2.31M | -146.37K | 949.21K | 828.95K | 584.02K | -152.15K | -668.73K | -903.22K | -755.31K | -709.41K | -485.41K | -293.61K |
Net Income | -16.81M | -16.5M | -16.48M | -4.62M | -2.99M | -1.57M | 657.37K | 949.16K | 828.91K | 583.68K | -152.73K | -669.31K | -904K | -755.75K | -709.75K | -485.75K | -293.75K |
Selling & General & Admin | 7.54M | 6.76M | 6.18M | 1.55M | 1.09M | 806.6K | 829.71K | 880.71K | 882.23K | 1.23M | 1.18M | 940.63K | 978.69K | 721.11K | 483.57K | 483.57K | 288.51K |
Research & Development | 5.44M | 5.82M | 6.2M | 3.52M | 2.75M | 1.79M | 535.68K | 681.00 | 681.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -12K | -4K | 14K | 24K | 2.09M | 2.08M | 2.08M | 2.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 12.97M | 12.57M | 12.4M | 5.09M | 5.93M | 4.68M | 3.44M | 2.95M | 882.91K | 1.23M | 1.18M | 940.63K | 978.69K | 721.11K | 483.57K | 483.57K | 288.51K |
Interest Expense | 11K | 2K | 2K | 2K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 12.97M | 12.57M | 12.4M | 5.09M | 3.86M | 2.62M | 1.38M | 881.39K | 882.91K | 1.23M | 1.18M | 940.63K | 978.69K | 721.11K | 483.57K | 483.57K | 288.51K |
Income Tax Expense | 5K | 10K | 15K | 19K | 17K | 12.01K | 6.01K | 10.00 | 10.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.78M | 9.24M | 6.48M | 4.3M | 1.12M | 971.2K | 5.53M | 6.61M | 12.06M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M |
Shares Outstanding (Diluted) | 6.78M | 9.24M | 6.48M | 4.3M | 1.12M | 971.2K | 5.53M | 6.61M | 12.06M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M | 16.51M |
EPS (Basic) | 17.82 | 16.81 | 15.22 | -3.06 | -3.01 | -1.72 | 0.09 | 0.10 | 0.08 | 0.04 | -0.01 | -0.04 | -0.05 | -0.05 | -0.04 | -0.03 | -0.02 |
EPS (Diluted) | 17.82 | 16.81 | 15.22 | -3.06 | -3.01 | -1.71 | 0.10 | 0.11 | 0.08 | 0.04 | -0.01 | -0.04 | -0.05 | -0.05 | -0.04 | -0.03 | -0.02 |
EBITDA | -16.91M | -16.43M | -12.46M | -5.16M | -3.52M | -2.28M | -64.43K | 949.15K | 828.89K | 583.68K | -152.73K | -669.31K | -904K | -755.75K | -709.75K | -485.75K | -293.75K |
EBIT | -16.93M | -16.46M | -12.5M | -4.39M | -2.74M | -1.49M | 730.69K | 949.13K | 828.88K | 583.68K | -152.73K | -669.31K | -904K | -755.75K | -709.75K | -485.75K | -293.75K |
Depreciation & Amortization | 21K | 25K | 43K | 31K | 24K | 16.02K | 10.02K | 15.00 | 15.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |